Version 1
: Received: 15 September 2023 / Approved: 15 September 2023 / Online: 18 September 2023 (02:32:17 CEST)
How to cite:
Arfenya, K.; Znamenskaya, L.; Vorontsova, A.; Obraztsova, O.; Nikonorov, A.; Nikonorova, E.; Deryabin, D.; Kubanov, A. Plasma Cytokines for Prediction of the Effectiveness of TNFα Inhibitors Etanercept, Infliximab, and Adalimumab in the Treatment of Psoriasis. Preprints2023, 2023091065. https://doi.org/10.20944/preprints202309.1065.v1
Arfenya, K.; Znamenskaya, L.; Vorontsova, A.; Obraztsova, O.; Nikonorov, A.; Nikonorova, E.; Deryabin, D.; Kubanov, A. Plasma Cytokines for Prediction of the Effectiveness of TNFα Inhibitors Etanercept, Infliximab, and Adalimumab in the Treatment of Psoriasis. Preprints 2023, 2023091065. https://doi.org/10.20944/preprints202309.1065.v1
Arfenya, K.; Znamenskaya, L.; Vorontsova, A.; Obraztsova, O.; Nikonorov, A.; Nikonorova, E.; Deryabin, D.; Kubanov, A. Plasma Cytokines for Prediction of the Effectiveness of TNFα Inhibitors Etanercept, Infliximab, and Adalimumab in the Treatment of Psoriasis. Preprints2023, 2023091065. https://doi.org/10.20944/preprints202309.1065.v1
APA Style
Arfenya, K., Znamenskaya, L., Vorontsova, A., Obraztsova, O., Nikonorov, A., Nikonorova, E., Deryabin, D., & Kubanov, A. (2023). Plasma Cytokines for Prediction of the Effectiveness of TNFα Inhibitors Etanercept, Infliximab, and Adalimumab in the Treatment of Psoriasis. Preprints. https://doi.org/10.20944/preprints202309.1065.v1
Chicago/Turabian Style
Arfenya, K., Dmitry Deryabin and Alexey Kubanov. 2023 "Plasma Cytokines for Prediction of the Effectiveness of TNFα Inhibitors Etanercept, Infliximab, and Adalimumab in the Treatment of Psoriasis" Preprints. https://doi.org/10.20944/preprints202309.1065.v1
Abstract
An analysis of the relationship between plasma cytokines and the effectiveness of treatment with TNFαinhibitors was performed in 81 patients with moderate-to-severe psoriasis. Treatment efficacy was assessed by PASI score, and patients were classified into a positive effect (PASI≥75) and no effect group (PASI≤50). A positive effect was reached in 11 (41%) patients for etanercept, 14 (52%) for adalimumab, and 26 (96%) for infliximab. Data analysis did not show differences in baseline TNFα levels and subsequent treatment effectiveness. The CART algorithm showed that at the baseline level of VEGF ≥ 32 pg/ml and IL17F < 26 pg/ml, there was an 83% probability of a positive effect. Random forest analysis showed the importance of VEGF, ICAM1, sCD40L, IL17F and IL31 baseline levels in the prediction of treatment effectiveness. Significant differences between the groups before/after the treatment were found only for TNFα: the median values were more than 50 times higher in no effect compared with positive effect group. There were differences before/after therapy in the levels of IL20, ICAM1, IL22, IL23 in the no effect group. The treatment affected the cytokine profile in most cases regardless of the effectiveness of therapy.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
